Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Helyezés a részvények között
#3419
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Részvényárfolyam
$4.48
Piaci kapitalizáció
$4.99B
Változás (1 nap)
-5.20%
Változás (1 év)
-41.89%
Ország
CN
Kereskedés Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategória
Healthcare
EPS Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) részvényre
EPS June 2026 dátummal, TTM: $0.09
Shenzhen Salubris Pharmaceuticals Co., Ltd. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $0.09. 2024 végén a vállalat EPS mutatója $0.07 volt, megegyezik a 2023 év EPS értékéhez, amely $0.07 volt.
Shenzhen Salubris Pharmaceuticals Co., Ltd. EPS története 2006 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $0.09 | 12.25% |
| 2025 | $0.08 | 12.03% |
| 2024 | $0.07 | 0.68% |
| 2023 | $0.07 | -12.60% |
| 2022 | $0.08 | 6.86% |
| 2021 | $0.08 | 764.84% |
| 2020 | $0.01 | -90.82% |
| 2019 | $0.10 | -50.96% |
| 2018 | $0.20 | -5.38% |
| 2017 | $0.21 | 11.48% |
| 2016 | $0.19 | 2.84% |
| 2015 | $0.19 | 15.43% |
| 2014 | $0.16 | 23.96% |
| 2013 | $0.13 | 33.13% |
| 2012 | $0.10 | 58.00% |
| 2011 | $0.06 | 20.19% |
| 2010 | $0.05 | 40.71% |
| 2009 | $0.04 | 66.36% |
| 2008 | $0.02 | 71.88% |
| 2007 | $0.01 | 91.04% |
| 2006 | $0.01 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $8.37 | 9,220.71% |
US
|
|
| $6.06 | 6,653.12% |
FR
|
|
| $5.00 | 5,470.16% |
JP
|
|
| $3.32 | 3,597.10% |
US
|
|
| $1.29 | 1,336.53% |
CH
|
